![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Lonza will develop, optimize, and qualify a method utilizing Neuron-Derived Exosomes, set to be integrated into the development program of PrimeC, a novel extended-release oral formulation of a unique fixed-dose combination of ciprofloxacin and celecoxib, by NeuroSense.
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: NeuroSense Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 09, 2024
Details:
Lonza will manufacture the ACU193 (sabirnetug) drug substance, the first monoclonal antibody candidate to enter the clinic developed to selectively target toxic soluble amyloid beta oligomers, which evidence indicates are a primary underlying cause of Alzheimer’s disease.
Lead Product(s): Sabirnetug
Therapeutic Area: Neurology Product Name: ACU193
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Acumen Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 04, 2024
Details:
Under the expanded collaboration, Vaxcyte will utilise existing Lonza infrastructure to advance clinical development and commercialization of Vaxcyte’s PCV candidates, VAX-24, a 24-valent pneumococcal conjugate vaccine and VAX-31, in both the adult and pediatric populations.
Lead Product(s): 24-valent Pneumococcal Conjugate Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: VAX-24
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Vaxcyte
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration October 16, 2023
Details:
The collaboration aims to support the manufacture of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with T1D, focusing on the VX-880 (STx-02) and VX-264 programs in clinical trials.
Lead Product(s): STx-02
Therapeutic Area: Endocrinology Product Name: VX-880
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: Vertex Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 26, 2023
Details:
The collaboration supports the development and manufacturing of ABL Bio’s new bispecific antibody product by leveraging Lonza’s GS Xceed® expression system which includes GS PiggyBac®, a highly efficient transposon-based gene integration technology.
Lead Product(s): Bispecific Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: ABL Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 04, 2023
Details:
Lonza will integrate Simris’ antibody-drug conjugate payload technology into the Lonza Bioconjugation Toolbox and will gain the exclusive right to offer the technology to new and existing customers seeking novel payloads to develop into ADC medicines.
Lead Product(s): Antibody-Drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Simris Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 10, 2023
Details:
Through the new agreement, McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates and antibody-drug conjugate.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: McSAF
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 18, 2023
Details:
The collaborations will enable the integration of McSAF Inside® and Cristal Therapeutic's CliCr®, into the Lonza Bioconjugation Toolbox and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates and antibody-drug conjugate.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Cristal Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 17, 2023
Details:
Under the agreement, Lonza will support the development and manufacturing of CTIM-76, a CLDN6 x CD3 bispecific antibody clinical candidate. The bispecific antibody-based therapy is being developed to redirect T-cell mediated lysis toward malignant cells expressing CLDN6.
Lead Product(s): CTIM-76
Therapeutic Area: Oncology Product Name: CTIM-76
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Context Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 09, 2023
Details:
Under the terms of the agreement, Lonza can now provide its customers with seamless access to Touchlight’s enzymatic DNA technology; a linear, covalently closed DNA vector, produced using an enzymatic manufacturing process.
Lead Product(s): mRNA-based Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Touchlight
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 06, 2022